Sitravatinib Catalog No.:M14117-2 BF738735 also impairs PI4KIIIα

BF738735 also impairs PI4KIIIα

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach

Tanomastat (BAY 12-9566) (100 mg/kg

Smiles: CC(=O)N[C@H]1[C@@H](OC(=C[C@@H]1N=C(N)N)C(O)=O)[C@H](O)[C@H](O)CO

Sitravatinib Catalog No.:M14117-2 BF738735 also impairs PI4KIIIαSitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1. 5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0. 5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively. Sitravatinib shows potent single agent antitumor efficacy and enhances the activity of PD 1 blockade through promoting an antitumor immune microenvironment. Product information CAS Number: